ArticleScientific reports2024
Stability study in selected conditions and biofilm-reducing activity of phages active against drug-resistant Acinetobacter baumannii.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Harnessing phage-ciprofloxacin synergy to overcome multidrug-resistant infections and biofilm persistence.Archives of microbiology · 2026Article
- Research progress on nanomaterials in promoting phage function and application.Applied and environmental microbiology · 2026Review
- Isolation and characterization of two phages infectingThe Journal of general virology · 2026Article
- Article
- Redefining Antimicrobial Resistance inInternational journal of molecular sciences · 2026Review
- Integrated wet lab and in silico discovery and characterization of bacteriophages with antibiotic synergy against multidrug resistant Acinetobacter baumannii.Scientific reports · 2026Article
- Isolation and characterization of a novel phage AbT1 and evaluating its anti-biofilm activity and antibiotic synergy.Molecular biology reports · 2026Article
- Phage vB_AbaM_MU1 for biocontrol of carbapenem-resistant Acinetobacter baumannii (CRAB) isolated from wound infection.Virology journal · 2026Article
- Isolation, characterisation and potential applications of a novel bacteriophage targeting beta-lactam-resistant Staphylococcus saprophyticus.Scientific reports · 2026Article
- Carbapenem-resistantMicrobiology spectrum · 2026Article
- Phage cocktails: state-of-the-art technologies and strategies for effective design.FEMS microbiology reviews · 2026Review
- Broad-spectrum phage cocktail targetingFrontiers in microbiology · 2026Article
- The isolation and characterisation of a temperate phage ɸPh_AJ01 against Acinetobacter junii.Virology journal · 2025Article
- Biological characterization and genome analysis of Pseudomonas phage ZAM-Pa99 as a promising anti-biofilm agent.Molecular biology reports · 2025Article
- A Newly DiscoveredAntibiotics (Basel, Switzerland) · 2025Article
- Fighting biofilm: bacteriophages eliminate biofilm formed by multidrug-resistant Enterobacter hormaechei on urological catheters.Medical microbiology and immunology · 2025Article
- In vitro, genomic characterization and pre-clinical evaluation of a new thermostable lytic Obolenskvirus phage formulated as a hydrogel against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Characterization and therapeutic potential of phage vB_Eco_ZCEC08 against multidrug-resistant uropathogenic Escherichia coli.BMC microbiology · 2025Article
- Characterization of holins, the membrane proteins of coliphage ASEC2201: a genomewideFrontiers in microbiology · 2025Article
- Beyond antibiotics: mesenchymal stem cells and bacteriophages-new approaches to combat bacterial resistance in wound infections.Molecular biology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Acinetobacter baumannii is currently a serious threat to human health, especially to people with immunodeficiency as well as patients with prolonged hospital stays and those undergoing invasive medical procedures. The ever-increasing percentage of strains characterized by multidrug resistance to widely used antibiotics and their ability to form biofilms make it difficult to fight infections with traditional antibiotic therapy. In view of the above, phage therapy seems to be extremely attractive. Therefore, phages with good storage stability are recommended for therapeutic purposes. In this work, we present the results of studies on the stability of 12 phages specific for A. baumannii under different conditions (including temperature, different pH values, commercially available disinfectants, essential oils, and surfactants) and in the urine of patients with urinary tract infections (UTIs). Based on our long-term stability studies, the most optimal storage method for the A. baumannii phage turned out to be - 70 °C. In contrast, 60 °C caused a significant decrease in phage activity after 1 h of incubation. The tested phages were the most stable at a pH from 7.0 to 9.0, with the most inactivating pH being strongly acidic. Interestingly, ethanol-based disinfectants caused a significant decrease in phage titers even after 30 s of incubation. Moreover, copper and silver nanoparticle solutions also caused a decrease in phage titers (which was statistically significant, except for the Acba_3 phage incubated in silver solution), but to a much lesser extent than disinfectants. However, bacteriophages incubated for 24 h in essential oils (cinnamon and eucalyptus) can be considered stable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.